Tuberculosis (TB) remains a leading cause of mortality across the globe, especially in high-burden regions like India. While the primary Bacillus Calmette-Guérin (BCG) vaccine provides essential protection for children, clinical researchers continue to debate the BCG revaccination efficacy in adults. A comprehensive systematic review and meta-analysis recently investigated whether a second dose of BCG truly strengthens the defense against Mycobacterium tuberculosis (MTB).

The analysis included six randomized controlled trials involving 2,400 participants to evaluate the clinical impact of revaccination. Notably, the study found that BCG revaccination did not result in a significant reduction in initial QuantiFERON (QFT) conversion (RR 0.99). Furthermore, the effect on sustained QFT conversion remained limited (RR 0.80), indicating only modest overall effectiveness. Consequently, these results suggest that the current revaccination strategy may not be sufficient to prevent MTB infection in high-risk populations.

Clinical Implications of BCG Revaccination Efficacy

The immunogenicity data revealed a distinct gap between immune markers and clinical outcomes. Researchers observed a moderate increase in CD8+ T cell and cytokine-producing CD4+ T cell responses. However, this robust immune activation did not translate into quantifiable protection against infection. Additionally, safety analysis indicated an increase in localized adverse events among revaccinated individuals. Interestingly, the data also highlighted a reduced risk of upper respiratory tract infections (RR 0.37), pointing toward potential non-specific protective effects of the vaccine.

Overall, the findings underscore the need for next-generation vaccines with proven protective immunity. While BCG revaccination induces cellular immune responses, its inability to significantly prevent QFT conversion suggests it should not be the sole focus for adult TB prevention. Therefore, clinicians must stay updated on emerging vaccine candidates that may offer more reliable protection for vulnerable groups.

Frequently Asked Questions

Does BCG revaccination prevent TB infection in adults?

According to the latest meta-analysis, BCG revaccination shows no significant effect on initial QFT conversion and only modest effectiveness against sustained infection, suggesting limited protective value.

What are the common side effects of BCG revaccination?

Revaccination is associated with an increased risk of localized adverse events, such as pain or swelling at the injection site, though it may unexpectedly reduce the risk of certain respiratory infections.

Why does immune activation not always lead to TB protection?

The study highlights a discrepancy where BCG boosts specific T-cell and cytokine responses, but these markers do not always correlate with a lower risk of acquiring or sustaining an MTB infection.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Ali SH et al. Efficacy, immunogenicity, and safety of BCG revaccination against Mycobacterium tuberculosis: A systematic review and meta-analysis. Hum Vaccin Immunother. 2026 Dec undefined. doi: 10.1080/21645515.2026.2630512. PMID: 41689765.

Schmidt AC et al. BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection. N Engl J Med. 2025 May 8;392(19):1797-1808. doi: 10.1056/NEJMoa2400843.